News

Fierce Pharma18h
Fierce Pharma Asia—Vor-RemeGen, Otsuka-Harbour autoimmune deals; Datroway's lung cancer nod
A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...
CURE4d
FDA Approves Datroway for EGFR-Mutated Advanced Lung Cancer
Datroway received accelerated FDA approval for adults with EGFR+ advanced non-small cell lung cancer after EGFR-targeted and ...
MPR2d
Datroway Gains Approval for Previously-Treated EGFR-Mutated NSCLC
The Food and Drug Administration (FDA) has granted accelerated approval to Datroway ® (datopotamab deruxtecan-dlnk) for adults with locally advanced or metastatic epidermal growth factor receptor ...
AstraZeneca and Daiichi Sankyo Treatment Wins First of Its Kind FDA Blessing to Treat Lung Cancer
Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its ...
Physician's Weekly1d
Nephron‑Sparing Techniques Improve Long‑Term eGFR Outcomes
Partial nephrectomy preserves renal function better than radical nephrectomy for complex tumors, especially in younger ...
PharmExec3d
FDA Grants Accelerated Approval to AstraZeneca, Daiichi Sankyo’s Datroway for Previously Treated, Locally Advanced or Metastatic EGFR-Mutated NSCLC
Approval was based on results from the Phase II TROPION-Lung05 trial, which showed that Datroway demonstrated a strong ...
pharmaphorum3d
AZ, Daiichi get Datroway nod in lung cancer on second try
AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate (ADC) Datroway has been granted accelerated approval ...
Fierce Pharma3d
AZ, Daiichi's Datroway scores its 2nd FDA approval—this time in lung cancer subset
The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal ...
PharmExec3d
AbbVie Positions Temab-A ADC for Tumor-Agnostic Use in Multiple Cancers
Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across ...
DATROWAY® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have ...